RBL 001/RBL 002/RBL 003/RBL 004

Drug Profile

RBL 001/RBL 002/RBL 003/RBL 004

Alternative Names: Lipo-MERIT; RB 0003; RB_0003; RBL001.1/RBL002.2/RBL003.1/RBL004.1; RBL001/RBL002/RBL003/RBL004; RNA-LPX; RNA(LIP); Tetravalent RNA-lipoplex Cancer Vaccine

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioNTech
  • Class Cancer vaccines; RNA vaccines; Synthetic vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Malignant melanoma

Most Recent Events

  • 27 Sep 2017 Preliminary immunogenicity data from a phase I trial in Malignant melanoma presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
  • 21 Aug 2017 Phase I/II development is ongoing in Germany (NCT02410733)
  • 01 Mar 2015 Phase-I/II clinical trials in Malignant melanoma in Germany (IV) (NCT02410733,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top